Borderline resectable pancreatic cancer: what have we learned and where do we go from here?
Open Access
- 7 December 2010
- journal article
- Published by Springer Science and Business Media LLC in Annals of Surgical Oncology
- Vol. 18 (3), 608-610
- https://doi.org/10.1245/s10434-010-1460-y
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Standardization of Surgical and Pathologic Variables is Needed in Multicenter Trials of Adjuvant Therapy for Pancreatic Cancer: Results from the ACOSOG Z5031 TrialAnnals of Surgical Oncology, 2010
- Borderline Resectable Pancreatic Cancer: Definitions and the Importance of Multimodality TherapyAnnals of Surgical Oncology, 2010
- Defining Venous Involvement in Borderline Resectable Pancreatic CancerAnnals of Surgical Oncology, 2010
- Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5‐fluorouracil, and cisplatin followed by radiotherapy and 5‐fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinomaJournal of Surgical Oncology, 2010
- Progress for resectable cancer?Cancer, 2010
- Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus StatementAnnals of Surgical Oncology, 2009
- Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus StatementAnnals of Surgical Oncology, 2009
- Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinomaThe American Journal of Surgery, 2008
- Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of DiseaseJournal of the American College of Surgeons, 2008
- Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative TherapyAnnals of Surgical Oncology, 2006